JP7682789B2 - Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 - Google Patents

Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 Download PDF

Info

Publication number
JP7682789B2
JP7682789B2 JP2021526660A JP2021526660A JP7682789B2 JP 7682789 B2 JP7682789 B2 JP 7682789B2 JP 2021526660 A JP2021526660 A JP 2021526660A JP 2021526660 A JP2021526660 A JP 2021526660A JP 7682789 B2 JP7682789 B2 JP 7682789B2
Authority
JP
Japan
Prior art keywords
cancer
antibody
cell
lymphoma
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526660A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020102779A5 (enExample
JP2022513053A (ja
Inventor
ジャン、シンシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of JP2022513053A publication Critical patent/JP2022513053A/ja
Publication of JPWO2020102779A5 publication Critical patent/JPWO2020102779A5/ja
Application granted granted Critical
Publication of JP7682789B2 publication Critical patent/JP7682789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021526660A 2018-11-16 2019-11-15 Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 Active JP7682789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768128P 2018-11-16 2018-11-16
US62/768,128 2018-11-16
PCT/US2019/061887 WO2020102779A1 (en) 2018-11-16 2019-11-15 MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2022513053A JP2022513053A (ja) 2022-02-07
JPWO2020102779A5 JPWO2020102779A5 (enExample) 2022-11-08
JP7682789B2 true JP7682789B2 (ja) 2025-05-26

Family

ID=70731685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526660A Active JP7682789B2 (ja) 2018-11-16 2019-11-15 Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用

Country Status (5)

Country Link
US (1) US12252538B2 (enExample)
EP (1) EP3880712A4 (enExample)
JP (1) JP7682789B2 (enExample)
CN (1) CN113330034A (enExample)
WO (1) WO2020102779A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4229091A4 (en) * 2020-10-15 2025-03-05 The Regents of the University of California ANTI-CANCER ANTIBODIES
CN115279417B (zh) 2021-02-09 2025-01-03 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
CN114380910B (zh) * 2022-01-07 2023-04-28 苏州旭光科星抗体生物科技有限公司 靶向人b7-h3分子的人源化单克隆抗体及其应用
CN118647408A (zh) 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
WO2023221975A1 (zh) 2022-05-18 2023-11-23 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
CN116063521B (zh) * 2022-10-31 2024-05-14 北京奇迈永华生物科技有限公司 靶向bcma的抗体及其所构成的嵌合抗原受体
WO2024106939A1 (ko) * 2022-11-15 2024-05-23 주식회사 셀랩메드 B7-h3에 특이적으로 결합하는 항체
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
WO2024238966A1 (en) * 2023-05-18 2024-11-21 RNAimmune, Inc. Anti-pd-l1 antibodies and uses thereof
WO2025019228A1 (en) * 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025146081A1 (zh) * 2024-01-03 2025-07-10 北京泰德制药股份有限公司 B7-h3结合蛋白

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016276A2 (en) 2004-08-03 2006-02-16 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
WO2011109400A2 (en) 2010-03-04 2011-09-09 Macrogenics,Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2012147713A1 (ja) 2011-04-25 2012-11-01 第一三共株式会社 抗ｂ７－ｈ３抗体
JP2017524725A (ja) 2014-05-29 2017-08-31 スプリング バイオサイエンス コーポレーション 抗ｂ７−ｈ３抗体及びその診断用途
WO2017214335A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2018177393A1 (zh) 2017-03-31 2018-10-04 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
EP1850860A2 (en) 2005-01-13 2007-11-07 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0908816D0 (en) 2009-05-21 2009-07-01 Royal Holloway University Of L Method
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CA2921639A1 (en) * 2013-09-05 2015-03-12 Aduro Biotech Holdings, Europe B.V. Cd70-binding peptides and method, process and use relating thereto
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
US10562952B2 (en) 2015-09-10 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 chimeric antigen receptors
HK1251475A1 (zh) * 2015-10-08 2019-02-01 Macrogenics, Inc. 用於癌症治疗的联合疗法
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10793636B2 (en) 2016-07-11 2020-10-06 Corvus Pharmaceuticals, Inc. Anti-CD73 antibodies
SG11201900677SA (en) 2016-07-28 2019-02-27 Novartis Ag Combination therapies of chimeric antigen receptors adn pd-1 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016276A2 (en) 2004-08-03 2006-02-16 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
WO2011109400A2 (en) 2010-03-04 2011-09-09 Macrogenics,Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2012147713A1 (ja) 2011-04-25 2012-11-01 第一三共株式会社 抗ｂ７－ｈ３抗体
JP2017524725A (ja) 2014-05-29 2017-08-31 スプリング バイオサイエンス コーポレーション 抗ｂ７−ｈ３抗体及びその診断用途
WO2017214335A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2018177393A1 (zh) 2017-03-31 2018-10-04 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AHMED. M et al.，Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3，The Journal of Biological Chemistry，2015年，Vol. 290, No. 50，pp. 30018-30029

Also Published As

Publication number Publication date
EP3880712A4 (en) 2022-11-16
US12252538B2 (en) 2025-03-18
US20220010018A1 (en) 2022-01-13
JP2022513053A (ja) 2022-02-07
EP3880712A1 (en) 2021-09-22
CN113330034A (zh) 2021-08-31
WO2020102779A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
JP7682789B2 (ja) Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用
US10781256B2 (en) Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies
JP7543247B2 (ja) ヒトＴｉｍ－３に対するモノクローナル抗体
JP2010509931A (ja) 新規抗増殖性化合物
CN121108344A (zh) 抗cd3抗体以及其用途
WO2021173844A1 (en) C19 c38 bispecific antibodies
EP4110818A1 (en) C19 c38 bispecific antibodies
TW202302650A (zh) 針對dll3的結合分子及其應用
CN114786720B (zh) TriAx抗体的组合物及其制备和使用方法
US12145989B2 (en) Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof
JP2024534116A (ja) 免疫抑制性ｂ細胞と関連付けられる癌を処置する方法
US20230312742A1 (en) CD38 antibodies for the treatment of human diseases
JP2020508636A (ja) ＩＦＮ−γ誘導性制御性Ｔ細胞転換性抗癌（ＩＲＴＣＡ）抗体およびその使用
CN116997356A (zh) 抗alpp/alppl2抗体和抗体-药物缀合物
HK40076734A (en) Composition of triax antibodies and method of making and using thereof
NZ736142B2 (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20231220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250514

R150 Certificate of patent or registration of utility model

Ref document number: 7682789

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150